ARDX

Ardelyx, Inc.

Fundamental data last updated:June 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/03/2026

Business Summary

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

 


Analyze ARDX on TradingView

VALUATION

P/E

-26.47

Market Cap ($M USD)

$1.54B

Forward P/E

2.81

PEG

0.00

PRICE TO SALES

3.61

PRICE TO BOOK

10.34

EV / EBITDA

-50.54

5-Year Average P/E

Free Cash Flow Yield

-2.43%

DCF Value

$-225.87

Graham Number

N/A

Price to FCF

-41.17

EV to FCF

-45.89

Earnings Yield

-3.78%

FCF Yield

-2.43%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.24

Next Year EPS Growth Estimate

$2.23

Next Year Revenue Growth Estimate

$140.85B

Return on Equity (ROE)

-38.11%

FREE CASH FLOW

Operating Margin

-8.75%

Debt-to-Equity

1.27

Piotroski F-Score

2

Altman Z-Score

1.12

Return on Invested Capital (ROIC)

-9.48%

Current Ratio

3.49

Quick Ratio

3.28

Net Debt to EBITDA

-5.20

Interest Coverage

-1.29

Gross Profit margin

91.93%

FCF PER SHARE

$-0.15

REVENUE PER SHARE

$1.74

Analyze ARDX on TradingView

Gainseekers Quantitative Analysis

Summary

The market’s current valuation of Ardelyx, Inc. seems to be a paradox wrapped in a biotech enigma. Despite a dismal DCF Value, the stock’s Forward P/E suggests optimism for future earnings, hinting at a potential turnaround. However, the negative Earnings Yield and a precarious Altman Z-score raise red flags about financial stability. The company’s valuation metrics, such as Price/Book and Price/Sales, appear stretched, indicating a disconnect between market expectations and intrinsic value. This stock is a high-stakes gamble, teetering on the edge of speculative fervor and genuine growth potential.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Ardelyx is inherently positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's rapid evolution towards tech-driven solutions could enhance their R&D efficiency. However, the company's ability to integrate these technologies effectively remains to be seen.

The Bull Case

For the bold investor, Ardelyx offers a tantalizing opportunity. The Forward PEG ratio is astonishingly low, suggesting the stock is undervalued relative to its growth prospects. Despite a negative ROIC, the company's impressive Sales Growth forecast and robust Current Ratio indicate potential for operational improvement. The Buy consensus rating adds a layer of institutional confidence, hinting at untapped pricing power and future capital efficiency.

The Bear Case

Yet, the bear case is hard to ignore. Ardelyx's Price/Book ratio is alarmingly high, signaling potential overvaluation. The negative FCF Yield and Price to FCF ratio reflect a troubling cash flow situation, exacerbated by a weak Piotroski F-Score. With a significant distance from its 52-week low, the stock appears technically overextended, suggesting limited upside without substantial operational improvements.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$17.00

Institutional Ownership %

1-Year Beta

0.61

Insider Buying % (6 Mo)

Distance to 52-Week High

34.40%

Distance to 52-Week Low

44.16%

EARNINGS SURPRISE %

-15.38%

50-DAY SMA

$6.16

200-DAY SMA

$6.14

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.